[February 26, 2015]

Research and Markets: Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2015 - 34 Companies & 38 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/47p8q8/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on lae-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Acceleron Pharma, Inc.
• Activartis Biotech GmbH
• AlphaMab Co., Ltd
• Amgen Inc.
• Angiogene Pharmaceuticals Ltd.
• Argos Therapeutics, Inc.
• Astellas Pharma Inc.
• Beta Pharma, Inc.
• Bionomics Limited
• Cerulean Pharma, Inc.
• Conkwest, Inc.
• Debiopharm International S.A.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Epirus Biopharmaceuticals, Inc.
• Exelixis, Inc.
• Genor BioPharma Co., Ltd.
• Hospira, Inc.
• immatics biotechnologies GmbH
• Immune Design Corp.
• Immunicum AB
• Inbiopro Solutions Pvt. Ltd.
• Jiangsu Hengrui Medicine Co., Ltd.
• Mabion SA
• NewLink Genetics Corporation
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Panacea Biotec Limited
• Peloton Therapeutics, Inc.
• Prima BioMed Ltd.
  

For more information visit http://www.researchandmarkets.com/research/47p8q8/metastatic_renal

[ Back To TMCnet.com's Homepage ]